News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
News Merck’s cardiovascular pipeline delivers at ACC Data on sotatercept in PAH and oral PCSK9 MK-0616 boost Merck's hopes for the franchise.
News Merck drops last phase 3 Keytruda trial in prostate cancer KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.
News Merck will appeal EU rejection of COVID drug Lagevrio CHMP says evidence for the drug is “not adequate” to show efficacy over standard care.
News Keytruda shadows GSK's Jemperli in endometrial cancer GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &
News Sanofi to buy UK vaccines developer Vicebio for $1.6bn Sanofi has agreed to buy UK start-up Vicebio, set up to produce improved, more potent shots that are simpler to manufacture, for $1.15bn upfront.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
